Article Text

Brief report on IQOS point-of-sale marketing, promotion and pricing in IQOS retail partner stores in Atlanta, Georgia, USA
  1. Katherine C Henderson1,
  2. Vuong Van Do1,
  3. Yu Wang1,
  4. Zongshuan Duan2,
  5. Lucy Popova1,
  6. Claire Adams Spears1,
  7. Scott R Weaver3,
  8. David L Ashley3,
  9. Dianne C Barker4,
  10. Jidong Huang1
  1. 1 Department of Health Policy and Behavioral Sciences, School of Public Health, Georgia State University, Atlanta, Georgia, USA
  2. 2 Department of Prevention and Community Health, School of Public Health, The George Washington University Milken Institute of Public Health, Washington, District of Columbia, USA
  3. 3 Department of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, Georgia, USA
  4. 4 Barker Bi-Coastal Health Consultant, Inc, Newport, Rhode Island, USA
  1. Correspondence to Dr Jidong Huang, Georgia State University, Atlanta P.O. Box 3995, USA; jhuang17{at}


Objectives Philip Morris has a history of aggressive marketing tactics in its global pursuit of IQOS sales, which extant literature suggests may appeal to non-smokers and young adults. This study was the first to examine point-of-sale (POS) marketing and pricing of IQOS after it entered the US market in October 2019.

Methods Trained field staff assessed 75 retail partner stores selling IQOS/HeatSticks in the Atlanta area in February–November 2020 using an IQOS-tailored, standardised assessment tool. The tool assessed store characteristics, product availability and accessibility, marketing and promotions and pricing for each store.

Results All stores assessed sold HeatSticks in at least one of the three flavours (tobacco, smooth menthol, fresh menthol), but did not sell the IQOS device. IQOS/HeatSticks marketing was present inside 98.5% and outside 17.3% of stores assessed. Marketing for other tobacco products was present inside 98.5% and outside 32% of stores. The average price per HeatSticks pack was US$6.40 compared with US$6.08 for Marlboro Red cigarettes.

Conclusion Our study revealed a considerable amount of POS marketing and promotion for IQOS/HeatSticks at retail partner locations, visible to all retail consumers, including youth and non-smokers. This study was the first to examine IQOS POS marketing and promotion in the US context and findings add to the extant literature on IQOS global marketing strategies. As additional novel tobacco/nicotine products continue to enter the market, targeted monitoring of the POS marketing and promotion for these new products is warranted.

  • non-cigarette tobacco products
  • advertising and promotion
  • price

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Tobacco product price and point-of-sale (POS) marketing influence consumer behaviours.

  • IQOS has a history of aggressive marketing techniques internationally.


  • This was the first study to examine IQOS POS marketing and price during its first year for sale in the US market.

  • Results showed high prevalence of IQOS marketing inside retail stores, with HeatSticks visible to all customers.


  • Postauthorisation POS marketing surveillance of the authorised tobacco products, as demonstrated in our study, may help inform regulatory agencies, such as the Food and Drug Administration, in determining whether to remove or amend product authorisation.


IQOS is a heated tobacco product (HTP) that claims to heat rather than burn tobacco to produce an inhalable aerosol.1 IQOS is available in over 60 countries and is continuing to expand, including to the USA where Food and Drug Administration (FDA) authorised Philip Morris (PM) to sell IQOS and three flavours of Marlboro HeatSticks in April 2019.2 3 PM subsequently opened its first US store in Atlanta, Georgia in October 2019.4–6 Although PM temporarily ceased US IQOS sales in November 2021 due to patent disputes with R.J. Reynolds and have not resumed sales at the time of writing,7 there remains a need for independent research examining US IQOS/HeatSticks early sales, use and marketing, which can provide information on the IQOS impact on public health as well as lending insight for the monitoring of other new tobacco/nicotine products authorised by FDA.

Despite PM’s claim that they market IQOS exclusively to adult smokers, existing international research raises concerns that IQOS/HeatSticks marketing and promotional strategies, such as marketing the device as a clean/chic product, may appeal to non-smokers and youth/young adults, which could lead to product initiation.8–16 Point-of-sale (POS) marketing is particularly important to examine, especially in countries with restrictions on other marketing avenues. Studies in Canada and Israel have found aggressive IQOS promotion tactics and prominent displays at POS, including marketing in the line of vision for youth.16 17 To our knowledge, there has been no research published examining the IQOS POS marketing and pricing strategies in the USA. The aim of this study was to fill this critical gap.


Setting and sampling

In Fall 2019, a list of 399 IQOS retailers in Atlanta, Georgia was retrieved from the PM website.18 Due to differences noted between the retail partner stores and IQOS specialty stores, only retail partner stores were assessed.6 See online supplemental table 1 for a description of these specialty stores. Thus, 3 flagship stores and 12 Corners/Mobile Retail Units were removed, resulting in a final list of 384 retail partner stores. From this list, 75 stores were randomly selected (stratified by income quintile), and 15 were selected as replacement stores, to be used in the event that a store did not sell IQOS/HeatSticks.

Supplemental material

IQOS retail assessment tool, training and data collection

The IQOS retail assessment tool was based on the Standardised Tobacco Assessment for Retail Settings (STARS) tool.19 The assessment tool (online supplemental table 2) was adapted to be specific to IQOS in the US market. It assessed store characteristics, product availability/accessibility, marketing/promotion and price (online supplemental table 1).

Supplemental material

Assessments were conducted by researchers from John Snow Inc, who received a 2-day in-person training including field practice. Two researchers visited each retail site at the same time and covertly collected data independently using paper assessments, explaining their presence only as needed.

The first 26 locations were assessed in February–March 2020, before a pause due to COVID-19. A 2-hour virtual re-training followed by practice field assessments occurred in June 2020 and data collection resumed July–November 2020, with one replacement store needed. Geographic locations of the final sample of stores are shown in online supplemental figure 1. Researchers returned to five of the stores assessed before COVID-19 to re-assess during COVID-19.

Supplemental material

Data analysis

Analysis was performed using Stata V.15 (StataCorp, College Station, Texas, USA) to obtain descriptive and Cohen’s kappa statistics. See online supplemental table 1 for a description of how disagreements were reconciled.


Before COVID-19 and during COVID-19 comparison and reliability

Because no notable differences were found for the five re-assessed stores from before versus during COVID-19, we combined the data. There was a high degree of reliability/agreement between the two independent coders (table 1) for all but two measures.20

Table 1

Store characteristics, product availability and accessibility, interior marketing and exterior marketing and price

Store characteristics, product availability/accessibility, marketing and price

Table 1 presents store characteristics, product availability/accessibility, interior and exterior marketing and price across the 75 IQOS retail partner stores. While all 75 stores (mostly convenience stores with age restriction signage) sold at least one flavour of HeatSticks, none of the retail partners directly sold the IQOS device at the time of assessment. All stores sold regular cigarettes and smokeless tobacco products, and most sold little cigars/cigarillos (98.7%) and e-cigarettes (68.0%). When available, all items were visible but not accessible by customers without help from a cashier.

Overall, 65 (98.5%) of the 66 stores with an interior had IQOS/HeatSticks marketing materials (referred to collectively as ‘IQOS marketing’) inside, with an average of 3.4 (range: 1–8) items per store. Similarly, 98.5% of stores had other tobacco (cigarettes, smokeless tobacco and/or little cigars/cigarillos) marketing inside. In addition, e-cigarettes were only sold in 51 stores, but 46 stores were found to have e-cigarette marketing inside. Interior IQOS marketing strategies focused on IQOS-branded signs (97.0%) and displays (60.6%). Among the stores with an interior, 28.8% had marketing saying IQOS is healthier or improved and 9.1% had promotions that advertised for HeatSticks multipack discounts.

On the exterior, 13 (17.3%) stores had some type of IQOS marketing materials, with an average of 2.5 (range: 1–4) items per store. Exterior marketing strategies focused on IQOS-branded signs (13.3%) and displays (5.3%). One store had HeatSticks pack special price promotions advertised outside. The proportion of stores with exterior IQOS marketing (17.3%) was lower than those with exterior e-cigarette (40.0%) and other tobacco (32.0%) marketing.

The average price for a pack of Marlboro HeatSticks was US$6.40 (SD=0.94), with 25 (33.8%) stores including a multipack discount in the price provided. In contrast, the average price for a pack of Marlboro Red cigarettes was US$6.08 (SD=0.83), with 41 (54.7%) stores including a discount in the price provided.


This study provides important initial findings on IQOS POS marketing and pricing practices in the first year of its launch in the USA. Our results show that the overall prevalence of IQOS marketing on the interior of the stores (98.5%) was comparable to other tobacco products (98.5%) and e-cigarettes (46 stores had marketing, only 51 sold the products), with HeatSticks visible to customers in 100% of stores. In addition, we found that the average price per pack of HeatSticks (US$6.40) was slightly higher than the average price per pack of Marlboro Reds (US$6.08). Overall, the assessment tool demonstrated high reliability across items.

Importantly, our results revealed a high prevalence of IQOS marketing inside retail stores in addition to having HeatSticks within full view (but not reach) of all customers, including youth and young adults. International studies have had similar findings.16 17 PM’s history of marketing IQOS internationally as a clean, chic, aspirational product,8 14 using packaging colours to represent flavours,17 hosting social events staffed by young adults,15 16 emphasising harm reduction14 21 and using young social media ‘influencers’22 suggests that IQOS marketing may appeal to youth, among whom interest, awareness and use of HTPs is on the rise.8 9 11 13 Marketing exposure, including POS marketing which is visible to all, may increase the risk of US youth and non-smokers initiating IQOS use, similar to what contributed to the existing vaping epidemic.23–25 It is therefore important for marketing and use of new products entering the market, like IQOS, to be monitored closely. This study adds to the literature on IQOS POS marketing and promotion strategies globally, and in the USA specifically and can inform the focus of future studies, not just for IQOS, but other novel tobacco products.

Our study has limitations. Our results may not be generalisable to other IQOS/HeatSticks sales locations as the investigation was only conducted in retail partner stores in Georgia selling HeatSticks and may not capture the full range of marketing aimed towards enticing new IQOS users. Overall, our results may not generalise over time since IQOS marketing may evolve and, for now, has been halted altogether. If IQOS is allowed to return to the market, further investigation would be required to capture new marketing strategies. Additionally, the first test market for IQOS was Atlanta but sales expanded to Virginia, North Carolina and South Carolina thereafter, which were not assessed.26 The future sales of IQOS in the USA are still uncertain, though, due to pending legal challenges.7

As IQOS and other novel tobacco/nicotine products enter new markets, studies monitoring their marketing and sales strategies should expand accordingly so that a picture of global marketing strategies can emerge. Independent research may benefit FDA in its decision to determine if there are grounds for withdrawing authorisation for these new products.3 If IQOS sales are allowed to resume in the USA, future research could build on our findings by increasing sample size and expanding geographically.


Using a retail assessment tool based on STARS and modified to be specific to IQOS, our assessment of 75 IQOS retail stores revealed a considerable amount of POS marketing and promotion, visible to all retail consumers, including youth and young adults, as well as non-smokers. As novel products such as IQOS continue to enter the US market, expanded monitoring of marketing and promotion strategies of these products is warranted.

Ethics statements

Patient consent for publication

Ethics approval

Not applicable.


We would like to thank John Wesley Heath and researchers at John Snow Inc for their assistance in data collection and data cleaning.


Supplementary materials


  • Twitter @JidongHuang

  • Contributors KCH led instrument design, oversaw data collection and led analysis, interpretation and writing. VVD contributed to data analysis and revised the manuscript. YW contributed to data analysis and revised the manuscript. ZD contributed to data analysis and revised the manuscript. LP contributed to conception and design of the study, contributed to funding acquisition and revised the manuscript. CAS contributed to the design of the study and manuscript revision. SRW contributed to the design of the study and manuscript revision. DLA contributed to the design of the study and manuscript revision. DCB advised on instrument design and revised the manuscript. JH led conception and design of the study, obtained funding and oversaw analysis, interpretation and writing.

  • Funding Research reported in this publication was supported in part by the National Institute of Drug Abuse of the National Institutes of Health and Food and Drug Administration Center for Tobacco Products (R01DA047397-02S1 to LP and DLA); the National Cancer Institute (R01CA194681-05S1 to JH) and the Robert Wood Johnson Foundation.

  • Disclaimer The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, Robert Wood Johnson Foundation and the Food and Drug Administration.

  • Map disclaimer The depiction of boundaries on this map does not imply the expression of any opinion whatsoever on the part of BMJ (or any member of its group) concerning the legal status of any country, territory, jurisdiction or area or of its authorities. This map is provided without any warranty of any kind, either express or implied.

  • Competing interests DLA has received funds for work done for the WHO Tobacco Free Initiative, as a Special Government Employee of the US Food and Drug Administration, as a consultant for Pfizer, as an employee of Cherokee National Operational Systems and as an independent contractor for McKing Consulting.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.